• NeoImmuneTech, Inc. (NIT) is currently under Phase I clinical trial in healthy normal volunteers, with strong non-clinical scientific evidences.
  • NIT will soon initiate single agent Phase Ib study in cancer patients in collaboration with major cancer centers and universities in the US and South Korea.
  • NIT pursues combination with leading immunotherapeutics such as an immune checkpoint inhibitor, a cancer vaccine, etc.
  • On top of its previous in vitro, in vivo studies, NIT has been conducting many proof-of-concept animal studies in parallel to progressing clinical trials in order to strengthen our beliefs and better design the clinical protocols. For instance, NT-I7 has demonstrated a strong enhancement of efficacy of HPV targeted therapeutic cancer vaccine when treated as a combination in a mice cancer model.